Phase 2 Schizophrenia Trial, Recruiting NCT04745143 Sponsor: China Medical University Hospital Condition: Schizophrenia
Back to Schizophrenia

Phase 2 Schizophrenia Trial, Recruiting

NCT04745143
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been officially diagnosed with schizophrenia according to standard psychiatric guidelines (DSM-5).
  • You either refuse to take antipsychotic medications or cannot tolerate them because they don't work well enough or cause bad side effects.
  • Your schizophrenia symptoms are rated at a certain level of severity based on a standard assessment score (confirm with trial site).
  • You have not taken any antipsychotic medications for at least one week before joining.
  • You are willing to take part in the study and have signed a consent form agreeing to participate.

Who may not be able to join:

  • You currently misuse substances (such as drugs or alcohol) or have had a dependency on them in the past 3 months.
  • You have a history of epilepsy, a serious head injury, stroke, or another significant medical or neurological condition that could affect the study.
  • You have received a long-acting injectable antipsychotic (a "depot" injection) within the past 3 months.
  • Your routine blood or lab tests show results that are a cause for medical concern (confirm with trial site).
  • You are currently pregnant or breastfeeding.
  • You are unable to follow the study's requirements and procedures.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 886 4 22052121

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
China Medical University Hospital
Registry
ClinicalTrials.gov
Start date
1 January 2018
Est. completion
1 September 2027

Where this trial is recruiting

🇹🇼 Taiwan

Primary endpoints

Change of Positive and Negative Syndrome Scale (PANSS); Change of scales for the Assessment of Negative Symptoms (SANS) total score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov